Overview

Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

Status:
Completed

Trial end date:
2019-10-08

Target enrollment:

Participant gender:

Summary

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease

Phase:

Phase 3

Details

Lead Sponsor:

Global Blood Therapeutics